Caribou Biosciences CRBU 深 沪
等待开盘 11-09 09:30:00 美东时间
0.4487
+0.036
+8.83%
华盛通- 最 高0.4487
- 今 开0.401
- 成交量 170.23万股
- 最 低 0.401
- 昨 收 0.4123
- 总市值 4847.61万
- 52周最高 2.49
- 市盈率 静 --
- 换手率 1.58%
- 52周最低 0.401
- 委 比 69.23%
- 总股本 1.08亿
- 历史最高 32.645
- 量 比 0.84
- 振 幅 11.57%
- 历史最低 0.401
- 每 手 1
- 风险率 0.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Caribou Biosciences 2026财年第3季度营收160.7万美元，同比下降26.89%
最新财报显示，Caribou Biosciences 2026财年第3季度实现： 营业收入：160.7万美元 同比：下降26.89% 净利润：-2661.2万美...
11-08 11:00
Caribou Biosciences Reports Third Quarter 2026 Financial Results
Caribou Biosciences reported Q3 2026 financial results, including $1.6M in licensing revenue, $21.3M in R&D expenses, and a GAAP net loss of $26.6M. The company announced a restructuring to explore strategic alternatives, including discontinuing vispa-cel and CB-011 trials and reducing workforce. Cash reserves stood at $94.8M. Vispa-cel and CB-011 are allogeneic CAR-T therapies with promising clinical data.
11-05 21:05
Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting
Caribou Biosciences announced that clinical abstracts for vispa-cel and CB-011 have been accepted for presentations at the 2026 ASH Annual Meeting in New Orleans. Despite plans to discontinue further development of these allogeneic CAR-T therapies due to financing challenges, investigators will present data from both programs. The oral and poster presentations will highlight long-term remissions and durable responses in patients with relapsed/ref...
11-04 14:00
Caribou Biosciences收涨3.95%，成交额143.79万美元
11月3日，Caribou Biosciences（CRBU）收涨3.95%，报0.44美元，成交额143.79万美元，市值4716.02万美元。 行情数据 ...
11-03 08:23
Caribou Biosciences收跌7.62%，成交额98.99万美元
10月27日，Caribou Biosciences（CRBU）收跌7.62%，报0.49美元，成交额98.99万美元，市值5276.72万美元。 行情数据 ...
10-27 07:23
Caribou Biosciences收涨1.12%，成交额136.01万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:28
美股大行评级 | 潜在涨幅175.74%！美光科技获DA Davidson上调目标价至3000美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持美光科技"买入"评级，目标价从2100美元升至3000美元；Leerink Partners：维持OmniAb"跑赢大市"评级，目标价从10美元升至12美元
10-08 12:30
Brookline Capital Downgrades Caribou Biosciences to Hold
Brookline Capital analyst Leah Cann downgrades Caribou Biosciences (NASDAQ:CRBU) from Buy to Hold.
10-07 23:06
Caribou Biosciences (CRBU) Shares Fall 35% After Hours: Here's Why
Caribou Biosciences Inc. (NASDAQ:CRBU) shares fell 35.07% to $0.74 in after-hours trading Tuesday after the company announced it is exploring strategic alternatives and plans to discontinue its two cell therapy programs. Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical...
10-07 13:34
Caribou Biosciences Mulls Strategic Options To Maximize Shareholder Value; Intends To Discontinue Further Development Activities For Two Allogeneic CAR-T Cell Therapy Programs
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it is exploring strategic alternatives to maximize stockholder value and plans to discontinue further development activities for its two allogeneic CAR-T cell ther...
10-07 04:07
